FOLH1 and prostate cancer: Disease-specific radiopharmaceuticals (including [177Lu]Lu–PSMA in prostate cancer, [177Lu]Lu/[90Y]Y-conjugated peptides in neuroendocrine tumors, [131I]Iodine in differentiated thyroid cancer, [131I]I-MIBG in pheochromocytomas/paragangliomas, etc.)provide simultaneous radiation to the skeletal and visceral lesions.